Paracelsis is an independent pharmaceutical contract research organisation (CRO) founded in 2012. Our mission is to provide our customers with a ‘one-stop’ solution with respect to their preclinical (nonclinical) development needs and our passion and sense of purpose, combined with integrity, high standards and excellent science are integral to what we do. We offer laboratory-based services to support the preclinical development of pharmaceutical products and drug delivery systems, etc. As a small CRO we pride ourselves on our ability to adapt to our customer’s needs and circumstances, as well as changes in the regulatory landscape. Combined with flexibility and a problem-solving attitude, we endeavor to meet the most challenging of budgetary and time constraints without compromise to our core values.
Paracelsis is also a toxicology consultancy service provider and, amongst other expertise, we regularly perform chemical hazard and risk assessments on active pharmaceutical ingredients and their metabolites, novel excipients, formulation impurities, degradation products, and extractables and leachables.
Some of the experimental studies conducted by Paracelsis involve the use of animals. As an organisation and as individuals, we are committed to the principles of the 3Rs concerning Replacement, Reduction, and Refinement of animals in research. All such work is subject to approval by an independent Animal Welfare and Ethical Review Board (AWERB) and is conducted to the highest standards of care and animal welfare under appropriate Home Office licensing authority.
Click here to find out more about our principles relating to the use of animals
Paracelsis’ founder and director, Michael Hinchcliffe (BSc(Hons), MSc, PhD), is a Fellow of the Royal Society of Biology (FRSB) (https://www.rsb.org.uk/) and a UK/EUROTOX Registered Toxicologist (ERT) (https://www.rsb.org.uk/careers-and-cpd/registers/uk-register-of-toxicologists) with extensive (>30 years) preclinical experience and a proven track record supporting market approval of pharmaceutical products in Europe, USA and Australia. Michael is a member of the British Toxicology Society (BTS) (https://www.thebts.org/). He has authored numerous publications (https://www.researchgate.net/profile/Michael_Hinchcliffe2).
Paracelsis is/has been involved in several grant-funded projects in association with academic colleagues at a number of UK Universities and we would welcome the opportunity for similar collaborations. Paracelsis could add a wealth of ‘preclinical’ knowhow and experience to your project team.